Related Experiment Video
Updated: May 2, 2026

Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases
Published on: January 1, 2016
Nerol as an anti-quorum sensing and therapeutic agent against Acinetobacter baumannii pneumonia
Qing Lu1,2, Shuyun Wei1,2, Yu Sun1,2
1Guangxi Technology Innovation Cooperation Base of Prevention and Control Pathogenic Microbes With Drug Resistance, Youjiang Medical University for Nationalities, Baise, Guangxi 533000, P.R. China.
Abstract:
Acinetobacter baumannii is a major nosocomial pathogen causing pneumonia; its virulence, biofilm formation, and antibiotic resistance are all regulated by quorum sensing (QS). Nerol, a monoterpene derived from orange peel, exhibits antibacterial activity. This study demonstrates that Nerol exhibits a minimum inhibitory concentration (MIC90) of 0.5 mg/mL against A. baumannii. At subinhibitory concentrations, it inhibits N-acyl-homoserine lactones, biofilm formation, motility, and extracellular polymeric substance (EPS) production. Proteomics revealed synchronous downregulation of virulence proteins, including BfmS, YiaD_1, MacB, MurF, and MtgA. ITC confirmed its 2:1 stoichiometric, exothermic binding to the BfmS sensor domain (KD 1.3 × 10-4 M), disrupting the BfmRS two-component system and blocking downstream QS pathways. Experiments demonstrated that Nerol significantly reduced the gene expression and protein secretion levels of proinflammatory cytokines (TNF-α, IL-6, and IL-1β) by inhibiting the activation of the NF-κB/MAPK signaling cascade. Nerol's ability to counteract QS and alleviate inflammatory responses highlights its potential as a therapeutic agent for treating A. baumannii infections.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
04:32Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
Related Concept Videos
Gene Regulation in Microbial Communities: Quorum Sensing
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Atypical Pneumonia
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Skeletal Muscle Relaxants: Therapeutic Uses